CN Patent

CN113387954B — 一种瑞德西韦中间体的制备方法

Assigned to Shanghai Institute of Materia Medica of CAS · Expires 2024-03-19 · 2y expired

What this patent protects

本申请提供一种瑞德西韦中间体(下式X所示的化合物)的制备方法。所述方法以修饰的杂环碱基、1’‑CN修饰的核糖等为起始物料，通过在酸或碱催化条件下偶联制备所述瑞德西韦中间体。本申请的合成方法具有物料成本低、污染物少、操作简便、条件温和等优点，适于开发为绿色可持续性的瑞德西韦生产工艺。

USPTO Abstract

本申请提供一种瑞德西韦中间体(下式X所示的化合物)的制备方法。所述方法以修饰的杂环碱基、1’‑CN修饰的核糖等为起始物料，通过在酸或碱催化条件下偶联制备所述瑞德西韦中间体。本申请的合成方法具有物料成本低、污染物少、操作简便、条件温和等优点，适于开发为绿色可持续性的瑞德西韦生产工艺。

Drugs covered by this patent

Patent Metadata

Patent number
CN113387954B
Jurisdiction
CN
Classification
—
Expires
2024-03-19
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Institute of Materia Medica of CAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.